Antonella Mazzei
Research Subjects
Antonella Mazzei has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Charlie Garnett-Benson
Bristol Myers Squibb, Princeton, New Jersey, USA
12 shared publications - Dirk Schadendorf
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
12 shared publications - Emilio Murillo
8iBiomed Clinical Research, Guadalajara, Mexico
12 shared publications - Erika Castillo Gutiérrez
FAICIC Clinical Research, Veracruz, Mexico
12 shared publications - Evan J. Lipson
Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
12 shared publications - Francisco Medina-Soto
Axis Heilsa S. de R.L. de C.V, Monterrey, Mexico
12 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Changes in immune cell populations in the NIVO + RELA arm from baseline to week 4.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Changes in immune cell populations in the NIVO + RELA arm from baseline to week 4.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Representativeness of study participants.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Representativeness of study participants.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Additional associations of on-treatment changes in CD8+ CM and CD4+ EM cell populations with best overall response.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Additional associations of on-treatment changes in CD8+ CM and CD4+ EM cell populations with best overall response.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Association between MHC-I or MHC-II and PFS or ORR in patients treated with NIVO + RELA or NIVO.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Association between MHC-I or MHC-II and PFS or ORR in patients treated with NIVO + RELA or NIVO.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Characterization of gene signatures in tumor samples associated with treatment arm, NIVO + RELA (A) versus NIVO (B); and type of response, CR/PR (C) versus PD (D).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Characterization of gene signatures in tumor samples associated with treatment arm, NIVO + RELA (A) versus NIVO (B); and type of response, CR/PR (C) versus PD (D).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
CD8 characterization in the TME.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
CD8 characterization in the TME.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Characterization of gene expression associated with (A) LAG-3 and (B) PD-L1 expression on immune and tumor cells.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Characterization of gene expression associated with (A) LAG-3 and (B) PD-L1 expression on immune and tumor cells.